Literature DB >> 35733001

NK Cell Effector Functions and Bystander Tumor Cell Killing in Immunovirotherapy.

Alessia Floerchinger1, Christine E Engeland2,3.   

Abstract

Oncolytic virotherapy is a compelling strategy to combine cancer gene therapy with immunotherapy. Lytic virus replication in malignant cells not only enables localized transgene expression based on engineered vectors but also triggers immunogenic tumor cell death and elicits inflammation in the tumor microenvironment. Modified oncolytic viruses encoding immunomodulators have been developed to enhance antitumor immune effects and therapeutic efficacy. As one example, bispecific molecules that engage immune cells to exert antitumor cytotoxicity can be encoded within the viral vector. This chapter describes an in vitro coculture experiment to study functionality and antitumor efficacy of engineered measles vaccine strain virus encoding natural killer cell engagers. In a flow cytometry-based analysis, target cell death of noninfected bystander cancer cells and effector functions of primary human natural killer cells are investigated. This methodology can facilitate assessment of advanced oncolytic viral vectors for cancer immunotherapy.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bispecific antibody; Cancer gene therapy; Cancer immunotherapy; Cytotoxicity assay; Killer cell engager; Measles virus; Vector design; Viral vectors

Mesh:

Year:  2022        PMID: 35733001     DOI: 10.1007/978-1-0716-2441-8_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  34 in total

Review 1.  Cytokines in oncolytic virotherapy.

Authors:  Jonathan G Pol; Samuel T Workenhe; Prathyusha Konda; Shashi Gujar; Guido Kroemer
Journal:  Cytokine Growth Factor Rev       Date:  2020-11-02       Impact factor: 7.638

Review 2.  New viruses for cancer therapy: meeting clinical needs.

Authors:  Tanner S Miest; Roberto Cattaneo
Journal:  Nat Rev Microbiol       Date:  2013-12-02       Impact factor: 60.633

Review 3.  Oncolytic viruses as engineering platforms for combination immunotherapy.

Authors:  Kwame Twumasi-Boateng; Jessica L Pettigrew; Y Y Eunice Kwok; John C Bell; Brad H Nelson
Journal:  Nat Rev Cancer       Date:  2018-07       Impact factor: 60.716

Review 4.  Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines.

Authors:  Stephen J Russell; Glen N Barber
Journal:  Cancer Cell       Date:  2018-04-09       Impact factor: 31.743

Review 5.  Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds.

Authors:  Venkatesh Sivanandam; Christopher J LaRocca; Nanhai G Chen; Yuman Fong; Susanne G Warner
Journal:  Mol Ther Oncolytics       Date:  2019-04-25       Impact factor: 7.200

Review 6.  Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.

Authors:  Johannes P W Heidbuechel; Christine E Engeland
Journal:  J Hematol Oncol       Date:  2021-04-16       Impact factor: 17.388

Review 7.  Oncolytic viruses: finally delivering.

Authors:  Leonard W Seymour; Kerry D Fisher
Journal:  Br J Cancer       Date:  2016-01-14       Impact factor: 7.640

Review 8.  Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.

Authors:  Carole Achard; Abera Surendran; Marie-Eve Wedge; Guy Ungerechts; John Bell; Carolina S Ilkow
Journal:  EBioMedicine       Date:  2018-04-23       Impact factor: 8.143

Review 9.  Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development.

Authors:  Nadishka Jayawardena; Laura N Burga; John T Poirier; Mihnea Bostina
Journal:  Oncolytic Virother       Date:  2019-10-29

Review 10.  Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.

Authors:  Tao Shi; Xueru Song; Yue Wang; Fangcen Liu; Jia Wei
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.